Insulet (NASDAQ:PODD) Shares Gap Up – Should You Buy?

Insulet Corporation (NASDAQ:PODD)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $138.97, but opened at $143.00. Insulet shares last traded at $144.3340, with a volume of 122,179 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PODD shares. JPMorgan Chase & Co. cut their target price on Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Robert W. Baird lowered their target price on Insulet from $360.00 to $248.00 in a report on Thursday, May 7th. Citigroup dropped their price target on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a research note on Thursday, May 28th. Royal Bank Of Canada restated an “outperform” rating and set a $280.00 price target on shares of Insulet in a report on Wednesday, May 27th. Finally, Barclays reduced their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a research report on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $238.67.

Insulet Stock Up 3.5%

The company has a market cap of $10.31 billion, a P/E ratio of 34.62, a PEG ratio of 1.13 and a beta of 1.13. The stock’s 50-day moving average price is $160.93 and its 200-day moving average price is $222.14. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The business had revenue of $761.70 million during the quarter, compared to analyst estimates of $729.89 million. During the same period in the previous year, the company posted $1.02 EPS. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, research analysts forecast that Insulet Corporation will post 6.46 EPS for the current year.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the acquisition, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. 0.36% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insulet

A number of large investors have recently modified their holdings of PODD. Larson Financial Group LLC raised its holdings in Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the fourth quarter valued at about $26,000. DV Equities LLC acquired a new position in shares of Insulet during the fourth quarter valued at about $28,000. Elyxium Wealth LLC bought a new stake in shares of Insulet during the fourth quarter worth about $28,000. Finally, Mcguire Capital Advisors Inc. bought a new stake in shares of Insulet during the fourth quarter worth about $29,000.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.